Major oral aphtous ulceration in HIV-1 infection: successful response after highly active antiretroviral therapy

被引：2
|
作者：
Dalmau, J. [1 ]
Alegre, M. [1 ]
Domingo, P. [1 ]
Alomar, A. [1 ]
机构：
[1] Hosp Santa Cruz & San Pablo, Dept Dermatol, E-08025 Barcelona, Spain
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2007年 / 21卷 / 01期
关键词：
D O I：
10.1111/j.1468-3083.2006.01812.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：126 / 127
页数：3
相关论文
共 50 条
  • [1] Successful treatment of major oral aphthous ulcers in HIV-1 infection after highly active antiretroviral therapy
    Alegre, M.
    Dalmau, J.
    Roe, E.
    Alomar, A.
    Domingo, R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (03) : 278 - 279
  • [2] Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection
    Hardy, G
    Worrell, S
    Hayes, P
    Barnett, CM
    Glass, D
    Pido-Lopez, J
    Imami, N
    Aspinall, R
    Dutton, J
    Gazzard, B
    Peters, AM
    Gotch, FM
    HIV MEDICINE, 2004, 5 (02) : 67 - 73
  • [3] Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection
    Rosenblatt, HM
    Stanley, KE
    Song, LY
    Johnson, GM
    Wiznia, AA
    Nachman, SA
    Krogstad, PA
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03): : 445 - 455
  • [4] Residual HIV-1 RNA after highly active antiretroviral therapy - Reply
    Pomerantz, RJ
    Zhang, H
    Dornadula, G
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09): : 1138 - 1139
  • [5] Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
    Rizzardi, GP
    Harari, A
    Capiluppi, B
    Tambussi, G
    Ellefsen, K
    Ciuffreda, D
    Champagne, P
    Bart, PA
    Chave, JP
    Lazzarin, A
    Pantaleo, G
    JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (05): : 681 - 688
  • [6] Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy
    Rockstroh, JK
    Mocroft, A
    Soriano, V
    Tural, C
    Losso, MH
    Horban, A
    Kirk, O
    Phillips, A
    Ledergerber, B
    Lundgren, J
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (06): : 992 - 1002
  • [7] Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
    Weverling, GJ
    Mocroft, A
    Ledergerber, B
    Kirk, O
    González-Lahoz, J
    Monforte, AD
    Proenca, R
    Phillips, AN
    Lundgren, JD
    Reiss, P
    LANCET, 1999, 353 (9161): : 1293 - 1298
  • [8] Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
    Grabar, S
    Le Moing, V
    Goujard, C
    Leport, C
    Kazatchkine, MD
    Costagliola, D
    Weiss, L
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 401 - 410
  • [9] Modeling the genetic control of HIV-1 dynamics after highly active antiretroviral therapy
    Ma, Chang-Xing
    Li, Yao
    Wu, Rongling
    CURRENT GENOMICS, 2008, 9 (03) : 208 - 211
  • [10] Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
    Zhang, LQ
    Chung, C
    Hu, BS
    He, T
    Guo, Y
    Kim, AJ
    Skulsky, E
    Jin, X
    Hurley, A
    Ramratnam, B
    Markowitz, M
    Ho, DD
    JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (07): : 839 - 845
12345